MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

25.08 4.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.08

Максимум

25.41

Ключови измерители
By Trading Economics
Приходи	10M 17M
Продажби	30M 130M
EPS	0.13
Марж на печалбата	13.432
Служители	354
EBITDA	11M 22M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+42.33% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-231M 3B
Предишно отваряне	20.93
Предишно затваряне	25.08

Настроения в новините

By Acuity

36%

64%

154 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.04.2026 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14.04.2026 г., 23:24 ч. UTC

Горещи акции

Stocks to Watch: Gloo, Broadcom, GitLab

14.04.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14.04.2026 г., 21:32 ч. UTC

Значими двигатели на пазара

GitLab Shares Rise on Expanded Google Cloud Collaboration

14.04.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14.04.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14.04.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14.04.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14.04.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14.04.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

14.04.2026 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 20:32 ч. UTC

Горещи акции

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14.04.2026 г., 19:59 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 19:38 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 19:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14.04.2026 г., 19:21 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14.04.2026 г., 19:09 ч. UTC

Придобивния, сливания и поглъщания

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

42.33% нагоре

12-месечна прогноза

Среден 34.33 USD 42.33%

Висок 36 USD

Нисък 31 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

154 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.